20348-23-6

Usage

Uses

Used in Dye and Pigment Production:
3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine is used as a precursor and intermediate in the production of various dyes and pigments, such as solvent violet 8 and insoluble pigments. Its unique chemical structure contributes to the color and stability of these products.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine is utilized as a key component in the synthesis of certain drugs. Its properties allow for the creation of new medicinal compounds with potential therapeutic applications.
Used in Polymer Production:
3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine is also employed in the manufacturing of polymers. Its incorporation into polymer structures can enhance their properties, such as stability, color, and other characteristics, depending on the specific application.
Used in Organic Compound Synthesis:
Due to its reactive nature and unique structure, 3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine serves as a valuable intermediate in the synthesis of a wide range of organic compounds, further expanding its utility across various chemical and industrial applications.

InChI:InChI=1/C7H8N2O/c1-2-6-7(8-3-1)9-4-5-10-6/h1-3H,4-5H2,(H,8,9)

Upstream product

• 20348-09-8 4H-pyrido[3,2-b][1,4]oxazin-3-one 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 34950-82-8 7-bromo-3,4-dihydro-2H-pyrido[3,2-β][1,4]oxazine 
• 149-73-5 trimethyl orthoformate 
• 959992-62-2 6-bromo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]oxazine 

Downstream Products

• 19612-61-4 4-Benzyl-3,4-dihydro-2H-pyrido<3,2-b>-1,4-oxazin 
• 34945-66-9 3,4-dihydro-2H-pyrido-[3,2-b][1,4]oxazine-7-carbonitrile 

Relevant academic research and scientific papers

RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

CYCLOPROPYL MIDA BORONATE

This disclosure concerns a protected cyclopropylboronic acid comprising a substituted cyclopropyl group and a boronic ester group having a protecting group. The protecting group is an N-methyliminodiacetic acid (MIDA) group or MIDA-based group.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME

In part, the present invention is directed to antibacterial compounds

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

FAB I INHIBITORS

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

Substituted biphenyl isoxazole sulfonamides

Compounds of the formula STR1 inhibit the activity of endothelin. The symbols are defined as follows: R1, R2, R3 and R4 are each directly bonded to a ring carbon and are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z1, Z2 and Z3 ; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) --C(O)H or --C(O)R5 ; (h) --CO2 H or --CO2 R5 ; (i) --Z4 --NR6 R7 ; (j) --Z4 --N(R10)--Z5 --NR8 R9 ; or (k) R3 and R4 together may also be alkylene or alkenylene, either of which may be substituted with Z1, Z2 and Z3, completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached; and the remaining symbols are as defined in the specification.